Analysts Set Assembly Biosciences, Inc. (NASDAQ:ASMB) Price Target at $41.25

Assembly Biosciences, Inc. (NASDAQ:ASMB) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $41.25.

A number of research analysts have recently weighed in on ASMB shares. Citizens Jmp began coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They set an “outperform” rating and a $38.00 price target on the stock. Citigroup assumed coverage on Assembly Biosciences in a report on Wednesday, September 24th. They set an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research note on Friday. Guggenheim increased their price objective on Assembly Biosciences from $31.00 to $39.00 and gave the company a “buy” rating in a report on Monday, September 8th. Finally, Zacks Research upgraded Assembly Biosciences to a “hold” rating in a report on Tuesday, August 19th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Assembly Biosciences by 6.9% during the second quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock valued at $925,000 after acquiring an additional 3,312 shares during the period. Ellsworth Advisors LLC acquired a new position in shares of Assembly Biosciences during the 3rd quarter worth about $852,000. Acadian Asset Management LLC boosted its stake in Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 6,823 shares during the period. Palumbo Wealth Management LLC grew its holdings in Assembly Biosciences by 3.8% in the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 681 shares during the last quarter. Finally, American Century Companies Inc. bought a new position in Assembly Biosciences in the 1st quarter worth approximately $113,000. Institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $29.24 on Friday. The firm has a market cap of $224.27 million, a price-to-earnings ratio of -5.24 and a beta of 0.60. The stock has a 50-day simple moving average of $25.28 and a 200-day simple moving average of $19.07. Assembly Biosciences has a 52-week low of $7.75 and a 52-week high of $31.11.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating the consensus estimate of ($1.73) by $0.40. The firm had revenue of $9.63 million for the quarter, compared to analyst estimates of $5.30 million. Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. As a group, equities research analysts predict that Assembly Biosciences will post -6.87 earnings per share for the current year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.